Analyst firms · BofA Securities · ESPR
BofA Securities ESPR price target and rating history
Esperion Therapeutics Inc. (ESPR) · Health Care
BofA Securities rates Esperion Therapeutics Inc. (ESPR) Underperform with a $2.50 price target, as of its latest action on Jun 20, 2024. It has published 5 rating actions on ESPR since February 2023, including 1 upgrade and 3 downgrades.
- Current rating
- Underperform
- Price target
- $2.50
- Median target, all firms
- Too few
- Actions on ESPR
- 5
BofA Securities price target on ESPR
Every BofA Securities rating on ESPR
- Jun 20, 2024
- Jan 3, 2024
- Jun 15, 2023
- Mar 16, 2023
- Feb 27, 2023
How other firms rate ESPR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Neutral | May 1, 2026 | |
| Piper Sandler | Overweight | $9 | Nov 25, 2025 |
Questions about BofA Securities and ESPR
- What is BofA Securities's price target for ESPR?
- BofA Securities's latest stated price target for Esperion Therapeutics Inc. (ESPR) is $2.50, from its action on Jun 20, 2024.
- What is BofA Securities's rating on ESPR?
- BofA Securities rates ESPR Underperform, a bearish rating, as of Jun 20, 2024.
- When did BofA Securities last change its view on ESPR?
- On Jun 20, 2024, BofA Securities downgrades to Underperform from Neutral, price target $2.50.
More ESPR rating histories
All BofA Securities ratingsESPR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.